Back to resultsComparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis
Primary Purpose
Esophagitis, Reflux, Esophagitis, Peptic
Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Dexlansoprazole MR
Dexlansoprazole MR
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Esophagitis, Reflux focused on measuring Erosive Esophagitis
Eligibility Criteria
Inclusion Criteria: Subjects must have successfully completed the Phase 3 Study T-EE04-084 (NCT00251693) or T-EE04-085 (NCT00251719); and have healed esophageal erosions proven by endoscopy. Complete healing was assessed for change in LA Esophagitis Classification grades A, B, C, or D to healed (defined as anything less than the criterion for Grade A). The subject was counted as healed if endoscopy findings did not meet the Grade A criterion. Exclusion Criteria: Use of prescription or nonprescription proton pump inhibitors (PPIs), histamine (H2) receptor antagonists, sucralfate, misoprostol, or prokinetics throughout the study Use of antacids (except for study supplied) throughout the study. Subjects using drugs with significant anticholinergic effects such as tricyclics who cannot stay on a stable dose throughout the study. Need for continuous anticoagulant therapy.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Placebo Comparator
Arm Label
Dexlansoprazole MR 60 mg QD
Dexlansoprazole MR 90 mg QD
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Crude Rate Analysis.
Crude rates analyzed maintenance of healed EE from baseline of this study and considered prematurely discontinued subjects as relapsed.
Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Life Table Method
Percentage of subjects who maintained complete healing of erosive esophagitis as assessed by endoscopy. In the life table method, subjects without post-baseline endoscopy were included as censored; subjects who did not have a recurrence of EE and did not complete the study were also considered censored.
Secondary Outcome Measures
Percentage of Days Without Daytime or Nighttime Heartburn as Assessed by Daily Diary-Median.
The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was reported.
Percentage of Days Without Daytime or Nighttime Heartburn as Assessed by Daily Diary-Mean.
The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was marked
Percentage of Days Without Nighttime Heartburn as Assessed by Daily Diary-Median.
The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked.
Percentage of Days Without Nighttime Heartburn as Assessed by Daily Diary-Mean.
The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00255151
Brief Title
Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis
Official Title
A Phase 3 Study to Evaluate the Safety and Efficacy of Dexlansoprazole MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis
Study Type
Interventional
2. Study Status
Record Verification Date
February 2012
Overall Recruitment Status
Completed
Study Start Date
January 2006 (undefined)
Primary Completion Date
November 2006 (Actual)
Study Completion Date
November 2006 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Takeda
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to assess the ability of once-daily (QD) treatment with Dexlansoprazole modified-release (MR) 60 mg and 90 mg and placebo in maintaining healing of erosive esophagitis (EE).
Detailed Description
This is a Phase 3, randomized, double-blind, multi-center, placebo-controlled, 6 month maintenance study. The study is designed to compare the efficacy and safety of daily Dexlansoprazole MR (60 mg and 90 mg) with that of placebo, in maintaining healing of erosive esophagitis.
Because the development plan for Dexlansoprazole MR formulation was revised, the results of 2 identical studies, T-EE04-086 (NCT00255164) and T-EE04-087 (this study, NCT00255151), were combined and analyzed as a single larger study referred to as study T-EE04-086. A total of 451 subjects were included in the combined analysis: 237 subjects were enrolled into Study T-EE04-086, and 214 subjects were enrolled into Study T-EE04-087.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Esophagitis, Reflux, Esophagitis, Peptic
Keywords
Erosive Esophagitis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
451 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Dexlansoprazole MR 60 mg QD
Arm Type
Experimental
Arm Title
Dexlansoprazole MR 90 mg QD
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Dexlansoprazole MR
Other Intervention Name(s)
TAK-390MR, Dexilant, Kapidex
Intervention Description
Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to six months.
Intervention Type
Drug
Intervention Name(s)
Dexlansoprazole MR
Other Intervention Name(s)
TAK-390MR, Kapidex, Dexilant
Intervention Description
Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to six months.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
Primary Outcome Measure Information:
Title
Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Crude Rate Analysis.
Description
Crude rates analyzed maintenance of healed EE from baseline of this study and considered prematurely discontinued subjects as relapsed.
Time Frame
6 months
Title
Percentage of Subjects Who Maintained Complete Healing of Erosive Esophagitis as Assessed by Endoscopy - Life Table Method
Description
Percentage of subjects who maintained complete healing of erosive esophagitis as assessed by endoscopy. In the life table method, subjects without post-baseline endoscopy were included as censored; subjects who did not have a recurrence of EE and did not complete the study were also considered censored.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Percentage of Days Without Daytime or Nighttime Heartburn as Assessed by Daily Diary-Median.
Description
The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was reported.
Time Frame
6 months
Title
Percentage of Days Without Daytime or Nighttime Heartburn as Assessed by Daily Diary-Mean.
Description
The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was marked
Time Frame
6 months
Title
Percentage of Days Without Nighttime Heartburn as Assessed by Daily Diary-Median.
Description
The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked.
Time Frame
6 months
Title
Percentage of Days Without Nighttime Heartburn as Assessed by Daily Diary-Mean.
Description
The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked.
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects must have successfully completed the Phase 3 Study T-EE04-084 (NCT00251693) or T-EE04-085 (NCT00251719); and have healed esophageal erosions proven by endoscopy. Complete healing was assessed for change in LA Esophagitis Classification grades A, B, C, or D to healed (defined as anything less than the criterion for Grade A). The subject was counted as healed if endoscopy findings did not meet the Grade A criterion.
Exclusion Criteria:
Use of prescription or nonprescription proton pump inhibitors (PPIs), histamine (H2) receptor antagonists, sucralfate, misoprostol, or prokinetics throughout the study
Use of antacids (except for study supplied) throughout the study.
Subjects using drugs with significant anticholinergic effects such as tricyclics who cannot stay on a stable dose throughout the study.
Need for continuous anticoagulant therapy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Director
Organizational Affiliation
Takeda
Official's Role
Study Chair
Facility Information:
City
Anniston
State/Province
Alabama
Country
United States
City
Hueytown
State/Province
Alabama
Country
United States
City
Huntsville
State/Province
Alabama
Country
United States
City
Tallassee
State/Province
Alabama
Country
United States
City
Tuscaloosa
State/Province
Alabama
Country
United States
City
Tucson
State/Province
Arizona
Country
United States
City
Little Rock
State/Province
Arkansas
Country
United States
City
North Little Rock
State/Province
Arkansas
Country
United States
City
Azusa
State/Province
California
Country
United States
City
Carmichael
State/Province
California
Country
United States
City
Cypress
State/Province
California
Country
United States
City
Fresno
State/Province
California
Country
United States
City
Los Angeles
State/Province
California
Country
United States
City
Modesto
State/Province
California
Country
United States
City
Newport Beach
State/Province
California
Country
United States
City
Oakland
State/Province
California
Country
United States
City
Orange
State/Province
California
Country
United States
City
San Diego
State/Province
California
Country
United States
City
Santa Maria
State/Province
California
Country
United States
City
Littleton
State/Province
Colorado
Country
United States
City
Longmont
State/Province
Colorado
Country
United States
City
Wheat Ridge
State/Province
Colorado
Country
United States
City
Bristol
State/Province
Connecticut
Country
United States
City
Newark
State/Province
Delaware
Country
United States
City
Fort Myers
State/Province
Florida
Country
United States
City
Miami
State/Province
Florida
Country
United States
City
Naples
State/Province
Florida
Country
United States
City
New Smyrna Beach
State/Province
Florida
Country
United States
City
Ocala
State/Province
Florida
Country
United States
City
Pembroke Pines
State/Province
Florida
Country
United States
City
Port Orange
State/Province
Florida
Country
United States
City
Saint Petersburg
State/Province
Florida
Country
United States
City
Sarasota
State/Province
Florida
Country
United States
City
Zephyrhills
State/Province
Florida
Country
United States
City
Atlanta
State/Province
Georgia
Country
United States
City
Champaign
State/Province
Illinois
Country
United States
City
Moline
State/Province
Illinois
Country
United States
City
North Chicago
State/Province
Illinois
Country
United States
City
Oak Forest
State/Province
Illinois
Country
United States
City
Springfield
State/Province
Illinois
Country
United States
City
Evansville
State/Province
Indiana
Country
United States
City
Indianapolis
State/Province
Indiana
Country
United States
City
Newburgh
State/Province
Indiana
Country
United States
City
Davenport
State/Province
Iowa
Country
United States
City
Kansas City
State/Province
Kansas
Country
United States
City
Wichita
State/Province
Kansas
Country
United States
City
Lexington
State/Province
Kentucky
Country
United States
City
Louisville
State/Province
Kentucky
Country
United States
City
Baton Rouge
State/Province
Louisiana
Country
United States
City
Chevy Chase
State/Province
Maryland
Country
United States
City
Prince Frederick
State/Province
Maryland
Country
United States
City
Jackson
State/Province
Mississippi
Country
United States
City
Jefferson City
State/Province
Missouri
Country
United States
City
Kansas City
State/Province
Missouri
Country
United States
City
Saint Louis
State/Province
Missouri
Country
United States
City
Missoula
State/Province
Montana
Country
United States
City
Egg Harbor Township
State/Province
New Jersey
Country
United States
City
Albuquerque
State/Province
New Mexico
Country
United States
City
Chapel Hill
State/Province
North Carolina
Country
United States
City
Charlotte
State/Province
North Carolina
Country
United States
City
Greensboro
State/Province
North Carolina
Country
United States
City
High Point
State/Province
North Carolina
Country
United States
City
Raleigh
State/Province
North Carolina
Country
United States
City
Wilmington
State/Province
North Carolina
Country
United States
City
Winston Salem
State/Province
North Carolina
Country
United States
City
Bismarck
State/Province
North Dakota
Country
United States
City
Akron
State/Province
Ohio
Country
United States
City
Columbus
State/Province
Ohio
Country
United States
City
Dayton
State/Province
Ohio
Country
United States
City
Mogadore
State/Province
Ohio
Country
United States
City
Oklahoma City
State/Province
Oklahoma
Country
United States
City
Medford
State/Province
Oregon
Country
United States
City
Portland
State/Province
Oregon
Country
United States
City
Philadelphia
State/Province
Pennsylvania
Country
United States
City
Warwick
State/Province
Rhode Island
Country
United States
City
Anderson
State/Province
South Carolina
Country
United States
City
Mt. Pleasant
State/Province
South Carolina
Country
United States
City
Sioux Falls
State/Province
South Dakota
Country
United States
City
Chattanooga
State/Province
Tennessee
Country
United States
City
Germantown
State/Province
Tennessee
Country
United States
City
Jackson
State/Province
Tennessee
Country
United States
City
Johnson City
State/Province
Tennessee
Country
United States
City
Kingsport
State/Province
Tennessee
Country
United States
City
Amarillo
State/Province
Texas
Country
United States
City
Conroe
State/Province
Texas
Country
United States
City
Dallas
State/Province
Texas
Country
United States
City
Fort Worth
State/Province
Texas
Country
United States
City
Houston
State/Province
Texas
Country
United States
City
Odessa
State/Province
Texas
Country
United States
City
Pharr
State/Province
Texas
Country
United States
City
Seguin
State/Province
Texas
Country
United States
City
Temple
State/Province
Texas
Country
United States
City
Salt Lake City
State/Province
Utah
Country
United States
City
Charlottesville
State/Province
Virginia
Country
United States
City
Norfolk
State/Province
Virginia
Country
United States
City
Richmond
State/Province
Virginia
Country
United States
City
Bellevue
State/Province
Washington
Country
United States
City
Lakewood
State/Province
Washington
Country
United States
City
Tacoma
State/Province
Washington
Country
United States
City
Milwaukee
State/Province
Wisconsin
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
19681809
Citation
Howden CW, Larsen LM, Perez MC, Palmer R, Atkinson SN. Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief. Aliment Pharmacol Ther. 2009 Nov 1;30(9):895-907. doi: 10.1111/j.1365-2036.2009.04119.x. Epub 2009 Aug 14.
Results Reference
result
Learn more about this trial
Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis
We'll reach out to this number within 24 hrs